HER2-Positive Breast Cancer Patients Prefer Faster Subcutaneous Administration Of Herceptin® (Trastuzumab) To IV

Further research also reveals quicker administration of Herceptin could save NHS £15m compared to current practice1 Results from the PrefHer (Patient Preference for Subcutaneous (SC) versus Intravenous (IV) Herceptin) trial show that 92% of early HER2-positive breast cancer patients favoured quicker SC administration of Herceptin compared to the standard IV infusion.1 Presented at the St. Gallen Breast Cancer Conference in Switzerland. The primary reasons for preferring SC administration given by patients in the trial were less pain/discomfort and time saving...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Breast Cancer Source Type: news